Literature DB >> 10630852

Progression of burn wound depth by systemical application of a vasoconstrictor: an experimental study with a new rabbit model.

J S Knabl1, W Bauer, H Andel, I Schwendenwein, P F Dado, M Mittlböck, W Römer, M S Choi, R Horvat, G Meissl, M Frey.   

Abstract

The final depth of a necrosis resulting from burn trauma is determined within 3 days. The zone of stasis has the potential for complete regeneration or there may be ischemic influences that lead to necrosis. In our model, we examined the dermal influence of vasoconstrictors with reference to the development of burn necrosis. On the backs of New Zealand white rabbits (4.0-4.5 kg) standardized lesions were made with a heated aluminum stamp at 80 degrees C, 14 s in duration. The lesions were intradermal, whereby the border zone of the coagulated tissue was found in the middle two quarters of the dermis in 100% of untreated animals after 72 h. For dermal vasoconstriction epinephrine in a dose of 0.5 microg/kg/min was used. There were two groups of seven animals each. One group received epinephrine and the dosage was dependent on the clinical state of the animal. Several cycles were administered within a 3-day period. The reduction of skin perfusion was documented by Laser-Doppler-flowmetry. After 3 days, the skin with the lesions was excised and using a hematoxylin dye, a histological examination followed. The parameter used to determine the efficacy was the thickness of the uncoagulated part of the excised dermis. Over a period of 48 h, an average of 2.3 epinephrine cycles of average of 88 min per animal in duration resulted in an average reduction of skin diffusion of 41%. The uncoagulated part of the dermis in the epinephrine group was 28.6% average; in the control group, this was 43.5%. The statistical analysis revealed significant differences with a p-value of 0.0312 (significant, when value is less than 0.05). The test results indicate that temporary reduction of skin perfusion through external administration of vasocontrictors may lead to progression of burn necrosis in our animal model. Clinically, this result indicates that for patients with burn injuries and systemic inflammatory response syndrome who have insufficient volume therapy, the administration of vasocontrictors may produce similar results in the injured area.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10630852     DOI: 10.1016/s0305-4179(99)00086-8

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  9 in total

1.  [Primary treatment of burn patients].

Authors:  G A Giessler; R Deb; G Germann; M Sauerbier
Journal:  Chirurg       Date:  2004-06       Impact factor: 0.955

Review 2.  [Burn trauma--Part 2. Anesthesiological, surgical and intensive care management].

Authors:  G A Giessler; T Mayer; T Trupkovic
Journal:  Anaesthesist       Date:  2009-05       Impact factor: 1.041

3.  Impact of shock requiring norepinephrine on the accuracy and reliability of subcutaneous continuous glucose monitoring.

Authors:  Ulrike Holzinger; Joanna Warszawska; Reinhard Kitzberger; Harald Herkner; Philipp G H Metnitz; Christian Madl
Journal:  Intensive Care Med       Date:  2009-04-07       Impact factor: 17.440

4.  Skin ph variations from the acute phase to re-epithelialization in burn patients treated with new materials (burnshield®, semipermeable adhesive film, dermasilk®, and hyalomatrix®). Non-invasive preliminary experimental clinical trial.

Authors:  E Osti
Journal:  Ann Burns Fire Disasters       Date:  2008-06-30

5.  Relation Between Gender and Concomitant Medications With Erythropoietin-Treatment on Wound Healing in Burn Patients. Post Hoc Subgroup-Analysis of the Randomized, Placebo-Controlled Clinical Trial "EPO in Burns".

Authors:  Christina Irene Günter; Felicitas Paula Ilg; Alexander Hapfelmeier; Silvia Egert-Schwender; Wolfgang Jelkmann; Shibashish Giri; Augustinus Bader; Hans-Günter Machens
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

6.  Chitosan film containing fucoidan as a wound dressing for dermal burn healing: preparation and in vitro/in vivo evaluation.

Authors:  Ali Demir Sezer; Fatih Hatipoğlu; Erdal Cevher; Zeki Oğurtan; Ahmet Levent Baş; Jülide Akbuğa
Journal:  AAPS PharmSciTech       Date:  2007-05-24       Impact factor: 3.246

7.  Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: a randomized clinical trial.

Authors:  Fabienne Venet; Jonathan Plassais; Julien Textoris; Marie-Angélique Cazalis; Alexandre Pachot; Marc Bertin-Maghit; Christophe Magnin; Thomas Rimmelé; Guillaume Monneret; Sylvie Tissot
Journal:  Crit Care       Date:  2015-01-26       Impact factor: 9.097

8.  Astaxanthin protects against early burn-wound progression in rats by attenuating oxidative stress-induced inflammation and mitochondria-related apoptosis.

Authors:  Quan Fang; Songxue Guo; Hanlei Zhou; Rui Han; Pan Wu; Chunmao Han
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

Review 9.  Vasoactive and/or inotropic drugs in initial resuscitation of burn injuries: A systematic review.

Authors:  Kristine Knappskog; Nina Gjerde Andersen; Anne Berit Guttormsen; Henning Onarheim; Stian Kreken Almeland; Sigrid Beitland
Journal:  Acta Anaesthesiol Scand       Date:  2022-06-16       Impact factor: 2.274

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.